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Abstract
Background  and  objectives:  residual  paralysis  following  the  use  of  neuromuscular  blocking
drugs (NMBDs)  without  neuromuscular  monitoring  remains  a  clinical  problem,  even  when  NMBDs
are used.  This  study  surveys  postoperative  residual  curarization  and  critical  respiratory  events
in the  recovery  room,  as  well  as  the  clinical  approach  to  PORC  of  anesthesiologists  in  our
institution.
Methods:  This  observational  study  included  415  patients  who  received  general  anesthesia  with
intermediate-acting  NMBDs.  Anesthesia  was  maintained  by  non-participating  anesthesiologists
who were  blinded  to  the  study.  Neuromuscular  monitoring  was  performed  upon  arrival  in  the
recovery  room.  A  CRE  was  deﬁned  as  requiring  airway  support,  peripheral  oxygen  satura-
tion <90%  and  90--93%  despite  receiving  3  L/min  nasal  O2,  respiratory  rate  >20  breaths/min,
accessory  muscle  usage,  difﬁculty  with  swallowing  or  speaking,  and  requiring  reintubation.
The clinical  approach  of  our  anesthesiologists  toward  reversal  agents  was  examined  using  an
8-question  mini-survey  shortly  after  the  study.
Results:  The  incidence  of  PORC  was  43%  (n  =  179)  for  TOFR  <0.9,  and  15%  (n  =  61)  for  TOFR  <0.7.
The incidence  of  TOFR  <0.9  was  signiﬁcantly  higher  in  women,  in  those  with  ASA  physical  status
3, and  with  anesthesia  of  short  duration  (p  <  0.05).  In  addition,  66%  (n  =  272)  of  the  415  patientsm  had  received  neostigmine.  A  TOFR  <0.9  was  found  in  46%  (n  =  126)
ostigmine.
objective  neuromuscular  monitoring  is  not  available,  PORC  remains
 the  use  of  NMBDs.  The  timing  and  optimal  antagonism  of  thearriving at  the  recovery  roo
of the  patients  receiving  ne
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neuromuscular  blockade,  and  routine  objective  neuromuscular  monitoring  is  recommended  to
enhance patient  safety.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
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Resumo
Justiﬁcativa  e  objetivos:  A  paralisia  residual  após  o  uso  de  bloqueadores  neuromusculares
(BNMs)  sem  monitorac¸ão  neuromuscular  continua  sendo  um  problema  clínico,  mesmo  quando
BNMs são  usados.  Este  estudo  pesquisou  a  curarizac¸ão  residual  pós-operatória  e  os  eventos  res-
piratórios  críticos  em  sala  de  recuperac¸ão,  bem  como  a  abordagem  clínica  da  CRPO  feita  pelos
anestesiologistas  em  nossa  instituic¸ão.
Métodos:  Este  estudo  observacional  incluiu  415  pacientes  que  receberam  anestesia  geral  com
BNMs de  ac¸ão  intermediária.  A  manutenc¸ão  da  anestesia  foi  feita  por  anestesiologistas  não  par-
ticipantes,  ‘‘cegos’’  para  o  estudo.  A  monitorac¸ão  neuromuscular  foi  realizada  no  momento  da
chegada à  sala  de  recuperac¸ão.  Um  ERC  foi  deﬁnido  como  necessidade  de  suporte  ventilatório;
saturac¸ão periférica  de  oxigênio  <90%  e  90-93%,  a  despeito  de  receber  3  L/min  de  O2  via  cânula
nasal; frequência  respiratória  >20  bpm;  uso  de  musculatura  acessória;  diﬁculdade  de  engolir
ou falar  e  necessidade  de  reintubac¸ão.  A  abordagem  clínica  de  nossos  anestesiologistas,  em
relac¸ão aos  agentes  de  reversão,  foi  avaliada  usando  um  miniquestionário  de  oito  perguntas
logo após  o  estudo.
Resultados:  A  incidência  de  CRPO  foi  de  43%  (n  =  179)  para  a  SQE  <0  e  15%  (n  =  61)  para  a  SQE
<0,7. A  incidência  de  SQE  <0,9  foi  signiﬁcativamente  maior  em  mulheres,  pacientes  com  estado
físico ASA  III  e  com  anestesia  de  curta  durac¸ão  (p  <  0,05).  Além  disso,  66%  (n  =  272)  dos  415
pacientes  que  chegam  à  sala  de  recuperac¸ão  haviam  recebido  neostigmina.  Uma  SQE  <0,9  foi
encontrada  em  46%  (n  =  126)  dos  pacientes  que  receberam  neostigmina.
Conclusão:  Quando  a  monitorac¸ão  neuromuscular  objetiva  de  rotina  não  está  disponível,  a  CRPO
continua  sendo  um  problema  clínico,  a  despeito  do  uso  de  BNMs.  O  momento  e  o  antago-
nismo ideais  do  bloqueio  neuromuscular  e  a  monitorac¸ão  neuromuscular  objetiva  de  rotina  são
recomendados  para  aumentar  a  seguranc¸a do  paciente.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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euromuscular  blocking  drugs  (NMBDs)  are  used  to  facilitate
ndotracheal  intubation  during  induction  of  anesthesia.
esidual  postoperative  paralysis  following  the  use  of
uscle  relaxants  agents,  known  as  postoperative  residual
urarization  (PORC),  may  increase  postoperative  pulmonary
omplications,  morbidity  and  mortality.1,2 For  many  years
 train-of-four  ratio  (TOFR)  of  0.7  was  considered  sufﬁcient
o  exclude  PORC;  nowadays,  however,  to  exclude  clinically
igniﬁcant  PORC  it  is  considered  that  the  TOFR  should
e  ≥0.9.3,4 PORC  is  associated  with  weakness  of  upper
irway  muscles,  airway  obstruction,  impaired  pharyngeal
unction  leading  to  increased  risk  for  aspiration,  inadequate
ecovery  of  pulmonary  function,  and  impaired  hypoxic  ven-
ilatory  response.2,5 The  incidence  of  PORC  in  the  recovery
oom/post-anesthesia  care  unit  (PACU)  varies  widely,  with
eported  frequencies  ranging  from  9  to  47%.2,6--9 Critical
espiratory  events  (CREs)  during  early  recovery  from
eneral  anesthesia  are  not  uncommon  and  their  etiology
s  multifactorial.  Anesthetic  variables  associated  with
S
g
a
tostoperative  CREs  include  the  use  of  opioids  and  NMBDs
uring  general  anesthesia.2,10
This  prospective  observational  study  aimed  to  deter-
ine  the  incidence  of  PORC  in  the  early  recovery  period,
nticholinesterase  application  ratios  and  doses,  adverse
espiratory  events  of  PORC,  and  the  current  approach  of
nesthesiologists  to  PORC  without  routine  monitorization  in
ur  institution.
aterials and methods
atients  and  study  protocol
his  prospective,  observer-blinded  observational  study  was
pproved  by  the  local  Ethical  Committee  (Clinical  Trial-
umber  024/2010).  A  total  of  415  patients  (ASA  Physical
tatus  1--3,  aged  18--65  years)  who  were  operated  under
eneral  anesthesia  using  intermediate-acting  muscle  relax-
nts  between  April  2010  and  June  2010  were  enrolled  in
he  recovery  room.  Exclusion  criteria  were  patients  with
ory  
d
i
m
n
o
o
(
s
(
e
S
A
t
I
s
b
C
p
S
M
t
a
K
t
u
i
t
s
R
A
e
d
p
o
Postoperative  residual  curarizationSurvey  of  postoperative  residual  curarization,  acute  respirat
neuromuscular  diseases,  severe  kidney  or  liver  diseases,
those  undergoing  total  intravenous  anesthesia,  and  patients
with  a  body  temperature  ≤35 ◦C.  Premedication  and  choice
of  anesthetic  protocol,  giving  anticholinesterase  were  left
to  the  discretion  of  the  anesthesiologist  in  charge  of  the
patient,  who  was  unaware  that  the  patient  was  to  be
included  in  this  study.
Data  collection
Patients  were  subject  to  routine  monitoring  immediately
after  arrival  at  the  recovery  room.  Patients’  electrocar-
diogram,  peripheral  oxygen  saturation  (SpO2),  non-invasive
blood  pressure,  and  body  temperature  (GeniusTM 2  IR  Tym-
panic  Thermometer  Ltd.,  Gosport,  UK)  were  measured,  and
supplemental  oxygen  (3  L/min)  was  provided  to  all  patients.
PORC  was  assessed  in  the  recovery  room  by  an  anesthesi-
ologist  unaware  of  the  study.  The  neuromuscular  function
of  the  Adductor  pollicis  muscle  was  monitored  using  the
TOF-Watch  SX® acceleromyograph.  The  skin  was  washed
with  alcohol,  and  an  acceleromyograph  probe  was  placed
on  the  distal  ventral  part  of  the  thumb.  The  remaining  ﬁn-
gertips  were  tightly  ﬁxed  with  tape.  The  ulnar  nerve  was
stimulated.  The  TOF  tracing  was  stabilized  by  administer-
ing  1  min  of  repetitive  TOF  stimulation  followed  by  a 5-s,
50-Hz  tetanic  stimulation,  and  then  another  3--4  min  period
of  repetitive  TOF  stimulation.  The  CAL  2  mode  was  used
to  determine  the  supramaximal  threshold  and  to  calibrate
the  transducer  of  the  acceleromyograph.  After  calibration
of  the  device,  the  ratio  of  three  values  was  recorded  having
assessed  the  three  TOFR  at  15-s  intervals  in  each  patient
and  we  use  mean  of  these  three  values.  Patients  with  a
TOFR  of  <0.7,  0.7--0.9,  and  >0.9  were  regarded  as  hav-
ing  severe  PORC,  mild  to  moderate  PORC,  and  sufﬁcient
neuromuscular  recovery,  respectively.  The  following  param-
eters  were  assessed  and  recorded  in  the  intraoperative
anesthesia  records:  age,  bodyweight  (BW),  type  of  surgery,
duration  of  anesthesia  (i.e.  period  between  induction  of
anesthesia  and  arrival  at  the  recovery  room),  the  type  of
intermediate-acting  NMBDs  used,  duration  of  the  last  NMBD
(period  between  the  last  NMBD  and  the  TOFR  recording  in  the
recovery  room),  neostigmine  dose  and  time  administered,
and  reversal  time  (period  between  neostigmine  administra-
tion  and  TOF  recording  in  the  recovery  room).  Moreover,
the  following  parameters  were  examined/recorded  to  assess
respiratory  status:  need  for  airway  support,  upper  airway
obstruction,  respiratory  rate,  accessory  muscle  use,  difﬁ-
culty  with  swallowing  or  speaking,  and  reintubation.
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Table  1  Demographic  and  anesthesiology  data  of  the  study  group
Gender
(M/F)  n/(%)
Age
(years)
Weight
(kg)
ASA
1/2/3
n  (%)
202(48.7)/213
(51.3)
43.87  ±  14.14  73.24  ±  13.06  159(38.3)/20
(48.4)/55(13.
Data are mean ± SD, or number of patients (n) and percent (%).
ASA, American Society of Anesthesiologists; Sevo, sevoﬂurane; Des, deevents  and  approach  of  anesthesiologists  57
Patients  with  a  peripheral  oxygen  saturation  (SpO2)  <90%
espite  3  L/min  O2 nasal  cannula  were  regarded  as  hav-
ng  severe  hypoxia,  those  with  90--93%  as  having  mild  to
oderate  hypoxia,  and  those  with  SpO2 >  93%  as  having
ormoxia.2,11 Approach  to  treatment  of  PORC  left  choice
f  anesthesia  unaware  of  the  study.  For  the  survey  part
f  this  study,  the  clinical  approach  of  our  anesthesiologists
n  =  21)  toward  neostigmine  was  explored  using  a  mini-
urvey  (8  questions)  shortly  after  the  clinical  study.12 These
anonymous)  questionnaires  were  collected  in  enclosed
nvelopes.
tatistical  analysis
ll  statistical  analyses  were  performed  using  SPSS  (the  sta-
istical  package  for  social  sciences)  Version  15.0  (SPSS,
nc.,  Chicago,  IL,  USA).  For  continuous  variables,  mean  and
tandard  deviation  were  presented;  for  categorical  varia-
les,  frequency  and  percentage  values  were  presented.
hi-square  test  and  Fischer’s  exact  test  were  used  to  com-
are  categorical  variables.  To  compare  the  two  groups,
tudent’s  t  test  was  used  for  parametric  conditions,  and
ann--Whitney  U  test  was  used  for  non-parametric  condi-
ions.  In  order  to  compare  three  or  more  groups,  one-way
nalysis  of  variance  was  used  for  parametric  conditions,  and
ruskal--Wallis  H  test  was  used  for  non-parametric  condi-
ions.  Predictor  factors  of  PORC  were  determined  through
nivariate  logistic  regression.  All  parameters  with  p  <  0.05
n  univariate  analyses  were  included  in  a  multivariate  logis-
ic  regression  model.  A  p-value  of  ≤0.05  was  considered
tatistically  signiﬁcant.
esults
 total  of  415  patients  met  the  inclusion  criteria  and  were
valuated.  Of  these,  255  underwent  non-abdominal  proce-
ures  and  160  underwent  abdominal  procedures.  Table  1
resents  the  demographic  data  and  clinical  characteristics
f  the  415  patients.he  incidence  of  PORC  was  43%  (n  =  179)  for  a  TOFR  <0.9,
nd  15%  (n  =  61)  for  a TOFR  <0.7.  The  TOFR  was  ≥0.9  in  56%
n  =  236)  of  the  all  patients.
 (n  =  415).
Duration  of
anesthesia
(min)
Type  of  surgery
Abdominal/
non-abdominal
(n)
Sevo/Des/Iso
n
1
3)
106.10  ±  45.98  160/255  300/84/31
sﬂurane; Iso, isoﬂurane.
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Table  2  Train-of-four  ratio  in  relation  to  demographic/clinical  data.
Characteristic  TOF  ratio  P  value
<0.7
(n  =  61)
0.7--0.8
(n  =  43)
0.8--0.9
(n  =  75)
>0.9
(n  =  236)
Age  (year)  49.9  ±  11.7a 46.5  ±  13.2a 46.6  ±  12.2a 41.0  ±  14.8  <0.001
Gender n  (%)
Male  24  (11.9)  21  (10.4)  30  (14.8)  127  (62.9)  0.038
Female 37  (17.4) 22  (10.3) 45  (21.1) 109  (51.2)
Weight (kg) 75.5  ±  14.8 72.8  ±  14.5 73.0  ±  13.0 72.8  ±  12.3 NS
ASA n  (%)
1  17  (10.7) 11  (6.9) 24  (15.1) 107  (67.3) 0.003
2 34  (16.9)  25  (12.4)  39  (19.4)  103  (51.2)
3 10  (18.2)  7  (12.7)  12  (21.8)  26  (47.3)
Duration of  anesthesia  (min) 83.9  ±  37.1a 95.6  ±  41.0a 95.9  ±  41.9a 116.9  ±  47.1  <0.001
TFL TOF  (min) 67.4  ±  27.3a 73.6  ±  28.4a 88.0  ±  37.7a,b 109.4  ±  43.0  <0.001
Reversal time  (min) 10.5  ±  4.4a,c 10.7  ±  4.2a,c 12.3  ±  4.8  12.4  ±  4.3b 0.040
Neosigmine  (mg) 1.3  ±  0.5 1.1  ±  0.3 1.3  ±  0.4 1.2  ±  0.4  >0.05
Body temp.  (OC) 35.7(0.4) 35.7  (0.3) 35.8  (0.3)  35.7  (0.4)  >0.05
ASA, American Society of Anesthesiologists; TOF, train-of-four; TFL TOF, time from last NMBD to TOF recording in recovery room (min);
reversal time, time between reversal and assessment of TOF ratio in recovery room (min).
a p < 0.001 versus TOF >0.9.
<
a
a
Nb p < 0.001 versus TOF <0.7.
c p < 0.05 versus TOF 0.8--0.9.
Most  of  the  patients  showing  insufﬁcient  recovery  (TOFR
0.7  and  <0.9)  were  female,  ASA  physical  status  3,  had
nesthesia  of  short  duration,  and  had  a  higher  than  average
ge  (p  <  0.05)  (Tables  2  and  3).
I
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Table  3  Logistic  regression  analysis  of  risk  factors  for  PORC.
OR  
Univariate  logistic  regression
Age  (year)  1.036
Gender (malea/female)  1.616
Weight (kg)  1.006
ASA
I* 1
II 1.958
III 2.295
Duration of  Anesthesia  (min)  0.987
Neuromuscular  blocking  drug
Atracuriuma 1  
Vecuronium  1.744
Rocuronium  2.640
TFL TOF  (min)  0.978
Neostigmine  administration  (noa/yes) 1.465
Reversal time  (min) 1.008
Neostigmine  dose  (mg)  1.271
Multivariate  logistic  regression
Age  (year)  1.039
Gender (male/female)  1.568
TFL TOF  (min)  0.980
R-Sup-NMBDs, Receiving supplementary NMBDs; TFL TOF, Time from las
95% CI, 95% Conﬁdence interval.
a Reference category.MBD  managementn  the  present  study,  the  moderate  muscle  relaxant  agents
sed  were  vecuronium,  rocuronium  and  atracurium,  which
%  95  CI  p
 1.021--1.051  <0.001
 1.092--2.391  0.016
 0.991--1.021  0.430
 1.272--3.014  0.002
 1.229--4.286  0.009
 0.982--0.991  <0.001
--
 0.601--5.063  0.306
 0.832--8.375  0.099
 0.972--0.984  <0.001
 0.968--2.219  0.071
0.979--1.037  0.602
 0.951--1.697  0.105
 1.022--1.056  <0.001
 1.010--2.433  0.045
 0.973--0.987  <0.001
t NMBD to TOF recording in recovery room (min); OR, Odd’s ratio;
Survey  of  postoperative  residual  curarization,  acute  respiratory  events  and  approach  of  anesthesiologists  59
Table  4  Administration  of  neostigmin  related  demographic  data.
Characteristic  Neostigmine  administration?  p  value
Yes  (n:272)  No  (n:143)
Age  (year)  45.06  ±  14.14  41.60  ±  13.90  0.017
ASA n  (%)
I  (n  =  159)  92  (57.9)  67  (42.1)  0.020
II (n  =  201) 138  (68.7)  63  (31.3)
III (n  =  55) 42  (76.4) 13  (23.6)
Duration of  anesthesia  (min) 95.61  ±  41.80 126.05  ±  47.09 <0.001
TFL TOF  (min) 83.42  ±  34.08 118.92  ±  46.34 <0.001
st NM
i
a
R
T
C
p
p
c
4
h
d
s
<
A
TASA, American Society of Anesthesiologists; TFL TOF, time from la
were  applied  in  335,  63  and  17  patients,  respectively.  TOFR
<  0.9  was  42.1%  for  vecuronium,  52.4%  for  rocuronium  and
29.4%  for  atracurium.
Reversal  of  NMB  agents
On  arrival  in  the  recovery  room,  65.5%  (n  =  272)  of  the  415
patients  had  received  neostigmine,  whereas  the  remainder
34.5%  (n  =  143)  had  not.  A  TOFR  <0.9  was  estimated  in  46.3%
(n  =  126)  of  the  patients  receiving  neostigmine,  and  in  14.7%
(n  =  40)  of  this  group  the  TOFR  was  <0.7.  Table  4  presents
data  on  neostigmine  administration  in  relation  to  demo-
graphic  characteristics.  Patients  receiving  neostigmine  were
of  higher  average  age,  had  anesthesia  of  shorter  duration,
and  the  period  between  administration  of  the  last  muscle
relaxant  and  TOFR  assessment  was  shorter.  Another  ﬁnd-
ing  was  that  the  neostigmine  dose  did  not  change  according
to  the  TOFR;  an  average  dose  of  20  ±  10  g/kg  neostigmine
was  applied.  In  patients  not  receiving  neostigmine,  the  aver-
age  time  after  the  last  NMBD  dose  was  118.92  ±  46.34  min,
compared  with  83.42  ±  34.08  min  in  those  who  received
neostigmine  (p  <  0.001).  The  period  between  the  administra-
tion  of  neostigmine  and  TOFR  assessment  was  10.5  ±  4.4  min
a
a
P
i
Table  5  Critical  respiratory  events  ratio  in  relation  to  the  TOF  ra
Variables  
<0.7  0.7--0.8  
SpO2 92.1  ±  3.7  94.3  ±  2.
Requiring Airway  support,  n  (%)
Yes (n  =  47)  20  (42.6)  4  (8.5)  
No (n  =  368)  41  (11.1)  39  (10.6)
Critical respiratory  events,  n  (%)
No (n  =  370)  33  (8.9)  39  (10.5)
Yes (n  =  45)  28  (62.2)  4  (8.9)  
Upper airway  obstruction  5  2  
Respiratory  rate  >20 18  2  
Accessory  muscle  usage  4  --  
Reintubation  1  --  
Data are mean ± SD, or number of patients and percent (%).
a p < 0.001 vs. TOF <0.7.
b p < 0.001 vs. TOF 0.9.BD to TOF recording in recovery room (min).
n  patients  with  a  TOFR  <0.7  and  12.4  ±  4.3  min  in  those  with
 TOFR  >0.9  min  (Table  2).
espiratory  status
able  5  presents  data  on  the  relation  between  PORC  and
REs.  Accordingly,  in  patients  with  a  TOFR  ≥0.7  the  SpO2 was
roportionally  high,  while  in  those  with  a  TOFR  <0.7  it  was
roportionally  low.  Use  of  airway  support  and  respiratory
omplications  were  higher  in  patients  with  TOFR  <0.7.  In  our
15  patients,  14  of  17  patients  (82.4%)  with  an  SpO2 ≤90%
ad  a  TOFR  ≤0.9.  Only  3  patients  (17.6%)  had  an  SpO2 ≤90%
espite  a TOFR  >0.9.  SpO2 was  ≥93%  in  307  patients.  Airway
upport  was  applied  in  42.6%  of  the  patients  with  a  TOFR
0.7,  and  in  31.9%  of  those  with  a  TOFR  >0.9  (Table  6).
pproaches  to  PORC  by  anesthesiologists
able  7  presents  the  results  of  our  mini-survey  among  our  21
nesthesiologists  shortly  after  the  clinical  study.  Of  these
nesthesiologists,  71%  (n  =  15)  thought  that  the  incidence  of
ORC  was  0--10%,  and  only  1  anesthesiologist  (5%)  mentioned
t  could  be  30--50%.  Eight  anesthesiologists  (38%)  always  use
tio.
TOF  ratio  p-Value
0.8--0.9  >0.9
9a,b 94.6  ±  2.7a,b 95.6  ±  2.5a <0.001
8  (17.0)  15  (31.9)  <0.001
 67  (18.2)  221  (60.1)
 69  (18.6)  229  (61.9)  <0.001
6  (13.3)  7  (15.6)
2  2
1  1
3  3
--  --
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Table  6  Peripheral  oxygen  saturation  (SpO2)  in  relation  to  adequate  recovery  of  TOF  (>  0.9)  and  inadequate  recovery  of  TOF
(<0.7).
Peripheral  saturation  TOF  <0.9
(n  =  179)
TOF  >0.9
(n  =  236)
p-Value
SpO2 n  (%)
<90%  (n  =  17)  14  (82.4)  3  (17.6)
90--93% (n  =  96)  60  (62.5)  36  (37.5)  <0.001
>93% (n  =  302)  105  (34.8)  197  (65.2)
Data are number of patients and percent (%).
Table  7  Attitudes  regarding  management  of  PORC  in  our  institution  (n  =  21anesthesiologists).
Question  Options  n  %
What  do  you  estimate  the  incidence  of  PORC  to  be  in  your  clinic? 0--10.0%  15  71
10.1--20.0%  3  14
20.1--30.0%  2  10
30.1--50.0% 1  5
50.1--70.0% --  --
When an  NMBD  has  been  given,  do  you  always  administer
neostigmine  at  the  end  of  surgery?
Yes 8  38
No 13  62
If answer  to  the  above  question  was  ‘No’  in  what
percentage  of  cases  do  you  omit  neostigmine?
1--25% 2  15
26--50% 5  39
51--75% 4  31
76--100% 2  15
How long  after  administration  of  neostigmine  do  you
extubate  your  patiens?
After  extubation  I  administer
neostigmine
1  5
5--10 min  18  86
11--15 min  2  10
What dose  of  neostigmine  do  you  usually  administer? 2.5  mg  1  5
<0.05 mg/kg  10  48
0.05 mg/kg  5  24
>0.05 mg/kg  --  --
<2.5 mg  5  24
Do you  have  any  concerns  regarding  the  adverse  effects  associated
with administration  of  neostigmine/antimuscarinic  drugs?
Yes  17  81
No 4  19
If ‘Yes’  to  the  preceding  question,  what  are  they? -  Hemodynamic  effects  14  67
- Respiratory  effects  8  38
- Increased  nausea  and  vomiting  10  48
- Inadequate  recovery  of
neuromuscular  function
4  19
- Other  1  5
Prior to  tracheal  extubation  the  TOF  monitors  should  be: <50--60%  --  --
61--70% 2  10
71--80% 4  19
80--90% 4  19
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Deostigmine  at  the  end  of  surgery.  Five  of  13  anesthesiolo-
ists  who  do  not  always  use  neostigmine  reported  that  they
se  it  at  a  rate  of  26%  and  50%.  Eighteen  anesthesiologists
86%)  administer  neostigmine  5--10  min  before  extubation,  2
dminister  it  10--15  min  before  extubation,  and  1  mentioned
hat  he  administered  it  after  extubation.  Of  these  21  anes-
hesiologists,  17  (81%)  had  concerns  about  the  side-effects
y  the  use  of  reversal  agents,  14  (67%)  about  hemo-
ynamic  side-effects,  10  (59%)  about  nausea/vomiting,
nd  8  (38%)  had  concerns  about  respiratory  side-effects.
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leven  anesthesiologists  (53%)  believed  that  the  TOFR
hould  be  0.9  or  higher  before  extubation  (Table  7).
iscussionn  the  present  study  which  included  415  patients,  the  inci-
ence  of  PORC  was  15%  in  those  with  a TOFR  <0.7  and
3%  in  those  with  a  TOFR  <0.9.  Furthermore,  the  rate
f  sufﬁcient  recovery  (TOFR  >0.9)  was  57%,  and  65.5%  of
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dSurvey  of  postoperative  residual  curarization,  acute  respirat
these  patients  had  received  neostigmine  at  an  average  dose
of  20  ±  10  g/kg,  generally  administered  10--12  min  before
extubation.
A  TOFR  <0.9  was  estimated  in  46%  of  the  patients  who
received  neostigmine  (n  =  126),  and  14%  (n  =  40)  of  this  group
had  a  TOFR  <0.7.  However,  among  our  21  anesthesiologists,
71%  (n  =  15)  believed  that  the  incidence  of  PORC  in  our  insti-
tute  was  0--10%.  The  study  also  shows  that  patients  with
insufﬁcient  recovery  (TOFR  <0.7  to  <0.9)  were  older  than
average,  more  often  female,  had  an  ASA  score  3,  and  a
shorter  duration  of  anesthesia.
Of  our  415  patients,  in  the  recovery  room  45  had  CREs
symptoms  and  62%  of  these  45  patients  had  a  TOFR  <0.7.  Of
the  total  group,  84%  had  a  TOFR  ≤0.9.
The  incidence  of  PORC  did  not  decrease  over  time.
In  other  randomized  prospective  studies,  the  incidence  of
PORC  was  reported  to  have  changed  in  relation  to  differ-
ences  between  the  study  designs.2,6--9 For  example,  Debaene
et  al.8 determined  the  percentage  of  patients  in  the  PACU
with  a  TOFR  <0.7  and  <0.9  after  receiving  a  single  intu-
bating  dose  of  an  intermediate-acting  NMBD  (vecuronium,
rocuronium,  or  atracurium).  Muscular  paralysis  was  not
antagonized  intraoperatively.  A  TOFR  <0.7  in  16%  of  patients
(15.9%  received  rocuronium,  16.9%  received  atracurium,
17%  received  vecuronium)  and  <0.9  in  45%  of  patients  (45%
received  rocuronium,  41.6%  received  atracurium,  46.8%
received  vecuronium)  were  observed  postoperatively  and
TOFR  >0.9  was  observed  in  only  55%  of  patients  in  the
recovery  room.8 In  our  study  we  found  that  TOFR  <0.9  was
42%  with  vecuronium,  52%  with  rocuronium  and  30%  with
atracurium.
Cammu  et  al.7 assessed  the  occurrence  of  PORC  in
patients  undergoing  outpatient  and  inpatient  surgical  pro-
cedures.  Neuromuscular  monitoring  and  reversal  agent  was
used  in  only  12%  and  25%  of  patients,  respectively.  A  TOFR
<0.9  was  found  in  47%  of  the  inpatients  and  in  38%  of  the
outpatients.
In  their  observational  study,  Butterly  et  al.1 reported
that  reversal  agents  are  frequently  used;  78%  of  their
study  population  received  neostigmine  at  a  mean  dose  of
2.5  (±1.2)  mg.  Basic  nerve  stimulators  were  applied  rou-
tinely  in  operating  rooms  and  anesthetizing  locations,  and
the  incidence  of  PORC  was  22%.  The  higher  incidence  of
PORC  in  our  institution  might  be  attributable  to  a  lower
anticholinesterase  application  rate  (66%),  a  lower  mean
neostigmine  dose  (20  g/kg),  lack  of  routine  neuromuscular
monitoring,  and  may  depend  on  low  awareness  for  PORC.
Antagonism  of  neuromuscular  blockade  with
cholinesterase  inhibitors  at  the  end  of  the  surgery  reduces
the  incidence  of  PORC,  the  length  of  stay  in  the  recovery
room,  and  pulmonary  complications.1,2,5,6,9,13 However,
the  moment  of  antagonism  plays  an  important  role  in
these  patients.  If  antagonism  is  performed  shortly  before
extubation,  the  neuromuscular  block  is  often  insufﬁciently
antagonized,  thus  increasing  the  risk  of  PORC.14 If  intra-
operative  objective  neuromuscular  monitoring  can  not
be  applied,  it  is  recommended  that  the  patient  be  con-
stantly  antagonized  long  before  extubation  to  avoid  PORC
associated  with  the  depth  of  neuromuscular  blockade.5,8
Muphy  et  al.9 investigated  the  incidence  of  PORC  in  the
recovery  room  and  in  the  pre-extubation  period  among  120
patients  (ASA  1--2)  using  rocuronium  under  intraoperative
(
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euromuscular  monitoring;  all  subjects  were  reversed  with
eostigmine  at  a  TOF  count  of  2--4.  The  average  period
rom  the  injection  of  neostigmine  to  the  recording  of  TOFR
t  the  time  of  extubation  regarding  the  clinical  criteria  was
 ±  6  min.  During  extubation,  the  percentage  of  patients
ith  a  TOFR  <0.7  was  58%  and  that  of  patients  with  a
OFR  <0.9  was  88%.  They  also  reported  that  the  period
rom  injecting  neostigmine  to  the  TOFR  assessment  in
he  recovery  room  was  19  ±  7  min;  the  incidence  of  PORC
as  8%  and  32%  for  patients  with  a  TOFR  ≤0.7  and  0.9,
espectively.9
Another  study  by  McCaul  et  al.14 included  40  patients  of
SA  I using  atracurium.  During  neuromuscular  block  antag-
nism,  the  TOFR  <0.7  patients  were  found  to  be  70%,  while
he  same  ratio  was  found  in  65%  of  the  patients  during  extu-
ation.  Compared  with  patients  with  a  PORC  TOFR  >0.7,
atients  with  a  TOFR  <0.7  during  extubation  had  shorter
rocedures,  and  deeper  neuromuscular  block  at  the  time  of
eostigmine  administration.  In  that  study,  it  was  established
hat  the  period  from  the  moment  the  muscle  relaxant  was
pplied  to  the  recording  TOFR  was  6  ±  1  min  for  patients  with
OFR  <0.7,  and  15  ±  4  min  for  those  with  a  TOFR  >0.7.14 In
he  present  study,  the  period  from  anticholinesterase  appli-
ation  to  TOFR  measurement  was  10.5  ±  4.4  min  for  those
ith  a  TOFR  <0.7  and  12.4  ±  4.3  min  for  those  with  q  TOFR
0.9,  which  supports  the  results  of  McCaul  et  al.  Further-
ore,  Baillard  et  al.6 investigating  435  patients  in  1995,  130
n  2000,  and  101  in  2002,  studied  the  factors  affecting  PORC
ith  early  changes  in  clinical  anesthesia  applications.  Within
his  period,  concomitant  with  an  increase  in  the  average
ge  of  the  patients,  their  weight,  duration  of  surgery,  use
f  intraoperative  neuromuscular  monitoring  and  reversal  of
esidual  paralysis,  the  incidence  of  PORC  showed  a marked
ecrease  from  60%  to  5%.
Postoperative  respiratory  events  are  the  most  com-
on  adverse  outcomes  associated  with  residual  paralysis
eported  in  both  observational  and  randomized  clinical
tudies.  In  1994,  Rose  et  al.10 prospectively  examined
atient  (age  >60  yr,  male  gender,  diabetic,  and  obese),
urgical  (emergencies  and  cases  >4  h)  and  anesthetic  fac-
ors  (premedication,  induction  with  thiopental,  fentanyl
2.0  g  kg−1,  fentanyl  and  morphine  combination,  and
tracurium  >0.25  mg  kg−1 h−1) associated  with  CREs  in  the
ACU.  Murphy  et  al.2 assessed  and  quantiﬁed  the  severity
f  neuromuscular  blockade  in  patients  with  signs  or  symp-
oms  of  CREs  in  the  PACU.  A  total  of  7459  patients  received
 general  anesthetic  during  the  1-year  study  period,  of
hom  61  (1%)  developed  a CRE.  Forty-two  of  these  patients
ere  matched  with  controls  and  constituted  the  study  group
or  statistical  analysis.  A  high  incidence  of  several  residual
lockades  was  observed  in  patients  with  CREs,  which  was
bsent  in  control  patients  without  CREs.2
In  another  randomized,  prospective  and  placebo-
ontrolled  trial,  Sauer  et  al.15 studied  the  effect  of  CREs
n  the  incidence  of  PORC  by  dividing  114  patients  into  a
eostigmine  and  placebo  group  after  general  anesthesia  in
he  PACU.  Among  patients  receiving  rocuronium,  39%  were
iscovered  to  have  CREs  and  the  incidence  of  hypoxemia
SpO2) was  signiﬁcantly  higher  in  the  placebo  group  than  in
he  neostigmine  group.
In  a  survey  comparing  PORC  in  the  USA  and  Europe,  the
se  of  routine  reversal  agents  was  18%  in  Europe  and  34%
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n  the  USA.12 The  incidence  of  neuromuscular  monitoring  in
he  operating  room  was  22.7%  in  the  USA  compared  with
0.2%  in  Europe.  In  Europe,  54%  of  the  participants  applied
eostigmine  3--5  min  before  extubation  and  only  5%  of  them
aited  ≥10  min;  in  the  USA  these  ﬁgures  were  39%  waited
--5  min,  46%  waited  6--10  min,  and  13%  waited  10  min  before
xtubation.  With  respect  to  the  neostigmine  dose,  60%  of
he  participants  from  Europe  administered  a  dose  of  2.5  mg,
hereas  49%  of  the  participants  in  the  USA  administered  this
rug  on  a  milligram  per  kilogram  basis  rather  than  a  ﬁxed
ose.  Most  participants  from  both  Europe  (83.7%)  and  the
SA  (86%)  reported  concerns  about  the  adverse  effects  of
nticholinesterases  and  antimuscarinic  drugs.12 In  our  insti-
ution,  routine  use  of  a  reversal  agent  is  similar  to  that  used
n  the  USA  (i.e.  38%).  Among  our  anesthesiologists,  a  lower
wareness  of  PORC  and  a  higher  incidence  of  meuromuscu-
ar  blockade  is  probably  associated  with  the  lack  of  routine
euromuscular  monitoring  in  our  institute.
The  present  study  has  some  limitations.  First,  because
t  is  difﬁcult  to  establish  a  cause-effect  relation  in  obser-
ational  studies,  we  may  not  have  revealed  other  factors
ffecting  PORC.  Second,  we  were  unable  to  establish  the
ncidence  of  PORC  or  the  depth  of  neuromuscular  block  dur-
ng  extubation  since  objective  neuromuscular  monitoring  is
ot  applied  in  any  of  our  operating  rooms.  Third,  the  CREs
ight  have  been  inﬂuenced  by  unknown  clinical  variables;
n  addition,  their  long-term  effects  remain  unknown  as  CREs
ould  only  be  monitored  before  departure  from  the  recovery
oom.  Fourth,  because  the  patients  stayed  in  the  recovery
oom  for  varying  lengths  of  time,  we  were  unable  to  check
he  effects  of  the  TOFR  in  relation  to  the  duration  of  stay  in
he  recovery  room.
In  summary,  when  routine  objective  neuromuscular
onitoring  is  not  available,  PORC  remains  a  clinical  prob-
em  despite  the  use  of  intermediate-acting  NMBDs.  Older
atients,  female  patients,  ASA  physical  status  3,  shorter
nesthesia  procedures,  patients  with  a  short  time  to  the
ast  NMBD  dose,  and  early  extubation  after  antagonism  of
 neuromuscular  blockade  may  be  at  risk  of  PORC  and  CREs.
he  timing  and  optimal  antagonism  of  the  neuromuscular
lockade,  and  routine  objective  neuromuscular  monitoring
s  recommended  to  enhance  patient  safety.onﬂicts of interest
he  authors  declare  no  conﬂicts  of  interest.
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